XJPX
6678
Market cap83mUSD
Oct 09, Last price
1,997.00JPY
1D
1.11%
1Q
-3.67%
Jan 2017
1.68%
IPO
81.00%
Name
Techno Medica Co Ltd
Chart & performance
P/E
12.43
P/S
1.18
EPS
160.65
Div yield, %
3.44%
Shrs. gr., 5y
-4.08%
Rev. gr., 5y
4.45%
Revenues
11.24b
+13.43%
Net income
1.07b
+6.61%
CFO
1.10b
+12.57%
Dividend
Mar 30, 202793 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes automated systems for test tube preparation, urine aliquot, and RFID-based management solutions for both biological specimens and blood transfusions. The company also supplies a diverse range of analytical instruments for measuring blood gases, electrolytes, erythrocyte sedimentation rates, nutrient levels, sugar and acid content, and for performing urine chemistry tests. Furthermore, Techno Medica provides electronic medical charting systems, various pre-analytical devices, essential consumables, and comprehensive after-sales support. Established in 1987, the company's main office is located in Yokohama, Japan.
Key people
Masato Takeda
Chief Director of Sales, Director of Main Office Sales, Director · since 2016
Yasushi Nakano
Chief Director of Research and Development, Director of Medical Solution Development in Main Research and Development Unit, Director · since 2019
Masatomo Saneyoshi
President, Chief Executive Officer, Representative Director · since 2014
Kazuto Tsugawa
Chief Director of Business Administration, Manager of Corporate Planning Office, Director · since 2018
Shinichi Matsuo
Independent Director · since 2018
Independent Director · since 2017
Independent Director · since 2016
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||